CURIS System, an advanced decontamination technology company and AST, an aseptic fill-finish processing technology company, have entered into a partnership to advance the biodecontamination of aseptic fill-finish isolators in pharmaceutical manufacturing.
This collaboration marks a significant step forward in the pharmaceutical manufacturing industry, as the two companies combine technologies to revolutionise the biodecontamination of aseptic fill-finish isolators using CURIS’s disruptive vapour decontamination technology.
The vapour decontamination technology can improve the biodecontamination cycle efficacy and times.
Designed from its inception to be a single, seamlessly integrated system, the integration of the CURIS 7000ei with AST’s isolated filling lines is unified under the ASTView HMI user interface for a single point of operation.
Automation with the patented 7000ei hydrogen peroxide delivery system increases efficacy margins and provides the fastest biodecontamination times on the market by dramatically decreasing cycle times, outgas time, and environmental risks.
The vapour decontamination technology can improve the biodecontamination cycle efficacy and times
Packaged in AST’s new state-of-the-art isolator designed and manufactured in collaboration with Germfree, CURIS technology with AST’s expertise in fill-finish production presents a one-stop solution for our customers.
This partnership not only promises enhanced operational efficiency, streamlined service, and a superior customer experience but also sets new benchmarks in sterility assurance and contamination control for excellence in the pharmaceutical industry.
CURIS System, known for its unparalleled material compatibility and microbial eradication, brings a new dimension to contamination control in aseptic processing.
Its technology is recognised for virtually eliminating outgassing, a common challenge in the industry, ensuring a safer and more efficient pharmaceutical manufacturing environment.
Continuing to challenge the status quo, CURIS succeeds where others fail, with game-changing patented hybrid hydrogen peroxide technology that is an EPA-registered sporicide in addition to being FDA and Annex 1 compliant.
When we set out to design a new isolator, our goal was to provide the industry with a truly superior solution
Frances Grinstead, CEO of CURIS System, said: “Joining forces with AST produces true innovation that is a differentiator for the clients we serve, ensuring they have access to the most cutting-edge, comprehensive end-to-end solution. This American-made solution promises to raise the standard of the fill-finish environment and uphold the highest levels of contamination control.”
Joe Hoff, President and CEO of AST, added: “Integrating CURIS’s superior technology into AST’s isolated filling lines bolsters our commitment to innovation and excellence. When we set out to design a new isolator, our goal was to provide the industry with a truly superior solution just as we did 14 years ago with the launch of the ASEPTiCell [trademarked], the industry’s first robotic, multi-format filling line. In the same way that flexible, multi-format processing has now become the standard in pharmaceutical manufacturing, we are confident that this latest innovation will set the standard for the industry in the years to come. The collaboration between CURIS System and AST is set to make a significant impact on the life sciences industry, driving innovation and setting new benchmarks for quality and efficiency in cGMP-compliant pharmaceutical manufacturing.”
